Provectus Biopharmaceuticals Inc

(PVCT)

By |

Profile

Provectus Biopharmaceuticals Inc is a Delaware corporation formed in 2002. The Company along with its subsidiaries is a development-stage biopharmaceutical company engaged in developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. It is developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. It holds a number of U.S. patents covering the technologies it has developed and is continuing to develop for the production of prescription drugs, non-core technologies and OTC pharmaceuticals.

Contact Information

Website: www.provectusbio.com
Email: info@reignsc.com
Main Phone: +1 866 594-5999
Address: 7327 Oak Ridge Highway
Address 2: Suite A
State: TN
City / Town: Knoxville
Country: USA
Postal Code: 37931

Issuer Information

Exchange: OTCQB
CEO: Joseph Segelman
Employees: 10
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Provectus Biopharmaceuticals Inc is a Delaware corporation formed in 2002. The Company along with its subsidiaries is a development-stage biopharmaceutical company engaged in developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. It is developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. It holds a number of U.S. patents covering the technologies it has developed and is continuing to develop for the production of prescription drugs, non-core technologies and OTC pharmaceuticals.

Contact Information

Website: www.provectusbio.com
Email: info@reignsc.com
Main Phone: +1 866 594-5999
Address: 7327 Oak Ridge Highway
Address 2: Suite A
State: TN
City / Town: Knoxville
Country: USA
Postal Code: 37931

Issuer Information

Exchange: OTCQB
CEO: Joseph Segelman
Employees: 10
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 0.068 $ 0.002 (3.03%)
Last Price 0.068 Change $ 0.002 Change % 3.03 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open 0.068 High 0.068 Low 0.067 Prev Close 0.066
Last Trade Volume 83,200 52 Wk Hi 0.0775 52 Wk Low 0.0111
Market Cap 26.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 387,591,975.00 EPS (TTM) -0.02 PE Ratio N/A Exchange OTCQB
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Peter R. Culpepper 1,000
Peter R. Culpepper 1,000
Eric A. Wachter 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 3.5 3.5 3.5 3.5
Low Target Price Estimate 3.5 3.5 3.5 3.5
Mean Target Price Estimate 3.5 3.5 3.5 3.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 12/07/15 12/07/15 12/07/15 12/07/15
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 0 0 0 1